Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is making its entry into the Hyderabad market through its unique asset-light business model
Subscribe To Our Newsletter & Stay Updated
